Literature DB >> 17214517

The lethality of Ku86 (XRCC5) loss-of-function mutations in human cells is independent of p53 (TP53).

Goutam Ghosh1, Gang Li, Kyungjae Myung, Eric A Hendrickson.   

Abstract

Ku86 is one of the two regulatory subunits of the DNA-PK (DNA-dependent protein kinase) complex that is required for DNA double-strand break repair in mammalian cells. In a previous study, by means of somatic gene targeting, we generated human cell lines deficient in Ku86 (XRCC5). Heterozygous human Ku86 cells exhibited a wide array of haploinsufficient phenotypes, including sensitivity to ionizing radiation, defects in DNA-PK and DNA end-binding activities, elevated levels of p53 (TP53) and gamma-H2AX foci, and a defect in cell proliferation with an increase in the frequency of aneuploid cells. Here we demonstrate that the overexpression of a human Ku86 cDNA complemented the deficiencies of these cells to wild-type levels. In contrast, Ku86 overexpression only partially rescued the telomere defects characteristic of Ku86 heterozygous cells and did not rescue their genetic instability. Additionally, in stark contrast to every other species described to date, we had shown earlier that homozygous human Ku86(-/-) cells are inviable, because they undergo 8 to 10 rounds of cell division before succumbing to apoptosis. The tumor suppressor protein p53 regulates the DNA damage response in mammalian cells and triggers apoptosis in the face of excessive DNA damage. Correspondingly, ablation of p53 expression has repeatedly been shown to significantly ameliorate the pathological effects of loss-of-function mutations for a large number of DNA repair genes. Surprisingly, however, even in a p53-null genetic background, the absence of Ku86 proved lethal. Thus the gene encoding Ku86 (XRCC5) is an essential gene in human somatic cells, and its absence cannot be suppressed by the loss of p53 function. These results suggest that Ku86 performs an essential role in telomere maintenance in human cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17214517     DOI: 10.1667/RR0692.1

Source DB:  PubMed          Journal:  Radiat Res        ISSN: 0033-7587            Impact factor:   2.841


  7 in total

1.  Mutations to Ku reveal differences in human somatic cell lines.

Authors:  Kazi R Fattah; Brian L Ruis; Eric A Hendrickson
Journal:  DNA Repair (Amst)       Date:  2008-04-01

2.  Ku80 facilitates chromatin binding of the telomere binding protein, TRF2.

Authors:  Lauren S Fink; Chad A Lerner; Paulina F Torres; Christian Sell
Journal:  Cell Cycle       Date:  2010-09-25       Impact factor: 4.534

Review 3.  The Ku complex: recent advances and emerging roles outside of non-homologous end-joining.

Authors:  Sanna Abbasi; Gursimran Parmar; Rachel D Kelly; Nileeka Balasuriya; Caroline Schild-Poulter
Journal:  Cell Mol Life Sci       Date:  2021-04-15       Impact factor: 9.261

4.  SCID dogs: similar transplant potential but distinct intra-uterine growth defects and premature replicative senescence compared with SCID mice.

Authors:  Katheryn Meek; Ari Jutkowitz; Lisa Allen; Jillian Glover; Erin Convery; Alisha Massa; Tom Mullaney; Bryden Stanley; Diana Rosenstein; Susan M Bailey; Cheri Johnson; George Georges
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

5.  PRKDC mutations in a SCID patient with profound neurological abnormalities.

Authors:  Lisa Woodbine; Jessica A Neal; Nanda-Kumar Sasi; Mayuko Shimada; Karen Deem; Helen Coleman; William B Dobyns; Tomoo Ogi; Katheryn Meek; E Graham Davies; Penny A Jeggo
Journal:  J Clin Invest       Date:  2013-06-03       Impact factor: 14.808

6.  Autoantibodies targeting telomere-associated proteins in systemic sclerosis.

Authors:  Brittany L Adler; Francesco Boin; Paul J Wolters; Clifton O Bingham; Ami A Shah; Carol Greider; Livia Casciola-Rosen; Antony Rosen
Journal:  Ann Rheum Dis       Date:  2021-01-25       Impact factor: 27.973

7.  Impact of the Ku complex on HIV-1 expression and latency.

Authors:  Gwenola Manic; Aurélie Maurin-Marlin; Fanny Laurent; Ilio Vitale; Sylvain Thierry; Olivier Delelis; Philippe Dessen; Michelle Vincendeau; Christine Leib-Mösch; Uriel Hazan; Jean-François Mouscadet; Stéphanie Bury-Moné
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.